Dutch biotech Citryll nabs €85M to position inflammatory antibody for a pharma buyernews2024-12-09T07:00:16+00:00December 9th, 2024|Endpoints News|
BioAge Labs scraps Phase 2 obesity trial just months after IPOnews2024-12-06T22:32:41+00:00December 6th, 2024|Endpoints News|
GSK’s third new pact of the week focuses on Alzheimer’s with startup Muna Therapeuticsnews2024-12-05T12:00:38+00:00December 5th, 2024|Endpoints News|
Nuvig raises $161M as it prepares for Phase 2 study in hot autoimmune fieldnews2024-12-05T12:00:16+00:00December 5th, 2024|Endpoints News|
GSK partners with Rgenta on RNA-targeted small molecules for oncology, other areasnews2024-12-04T13:00:59+00:00December 4th, 2024|Endpoints News|
Ro’s weight loss business more than doubled in the last year. Now it’s trying to prove its program worksnews2024-12-04T13:00:20+00:00December 4th, 2024|Endpoints News|
Dewpoint partners its ALS program, eyes JPM to raise a Series Dnews2024-12-04T13:00:06+00:00December 4th, 2024|Endpoints News|
On heels of MariTide data, Danish obesity biotech discloses €80M Series Anews2024-12-04T08:00:57+00:00December 4th, 2024|Endpoints News|
After deal about-face and a spinout, Maze assembles $115M Series Dnews2024-12-03T14:07:01+00:00December 3rd, 2024|Endpoints News|
Gilead makes another ADC move, inking up to $415M pact with Tubulisnews2024-12-03T12:00:44+00:00December 3rd, 2024|Endpoints News|
